Drug Profile
Anti-HIV lipopeptide vaccine
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator CNRS; INSERM
- Developer CNRS; INSERM; Sanofi
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 18 Apr 2002 Phase-I clinical trials in HIV infections prevention in France (Injection)